Cambrian Biopharma

The journey from discovery to medical breakthrough demands imagination, speed, and focus. At Mission BioCapital, we provide early-stage capital to the next generation of awesome life science entrepreneurs and the platform where they can realize their visions. This approach has revolutionized the way life science start-ups progress from idea to key data through a model that champions collaboration at the center of everything we do. Our team has a deep-rooted commitment to empowering exceptional life science entrepreneurs from all walks of life. From your first experiment in our shared lab space through to the clinic, we want to be your partner in accelerating development of scientific solutions – faster, focused and more efficiently – to individuals and communities in most need. We’re there, from idea to exit. We are scientists, investors, founders, and serial entrepreneurs. Our team has a long history together, investing in, launching, and building dozens of early-stage life science companies. Making Transformational Investments. Founded in 2009, we are now investing out of our fifth fund. Since our inception, we have invested in early-stage life science companies following the same core principles: Mentorship and Collaboration – within our team and with founders Innovation and Creativity – in how we structure our investments and find solutions to problems; we are entrepreneurs too! Respect and Support – for the founders we work with

We support the development of novel medicines that address significant unmet medical needs. As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making. Investment strategy and approach Our investment and portfolio construction strategy builds on lessons learned and approaches perfected during the 15 years the founding team worked together. We invest in companies that are about to enter the most value-generating phase of drug development i.e. clinical stage. Our capital helps answer the question “Is there a drug that works here?” We can lead, co-lead or follow. We (almost) always take Board seats in companies we invest in and lay particular emphasis on aligning our investment objectives to fellow investors’ investment interests. We always reserve capital for future capital raises and do not do investments in which we cannot. We invest in companies where it is possible for a private investor or venture syndicate to finance the R&D program all the way to regulatory approval. Therapeutic area focus All modalities and therapeutic areas are in scope as long as the biotech company is developing a novel medicine. Out of scope are investments that are, in our judgment, incremental innovation or a pureplay regulatory or pricing story. Medical devices, digital health and diagnostics companies are out of scope. Stage of company We invest in about-to-be clinical and clinical stage companies where the investment will result in a clinical readout for the lead asset. We can invest in any private financing round irrespective of whether its termed Series A, B, C or Cross-over Platform companies are also attractive, as long as the lead asset will get to a clinical readout with the financing. Geographic footprint We invest in companies in Europe and United States. We lay particular emphasis in investing in companies with Scandinavian roots, like our Firm has, and often start and build companies in Swedish and Danish ecosystem. Diseases afflicting people does not recognize geographic boundaries, science is global, financial capital is globally distributed and human capital is globally mobile. Therefore, we believe companies need to be built with that global perspective in mind. Our Core Values DECENT We show respect at all times We act with integrity and always aim to do the right thing Being reasonable builds long-term relationships DEDICATED We work hard to deliver results for patients, our companies and our LPs We are highly professional We love what we do CONFIDENT Our combined experience is extensive – we have been there before We trust our capabilities We are supported by a strong and extensive network HUMBLE We know our limitations We know when to listen and when to ask questions We are responsible stewards of our LP’s capital

Trinity Innovation Bioventure Singapore is a licensed biomed venture capital fund focusing on innovation and value investment with deep insight and experience on Asia markets. We are part of the Trinity Innovation Fund group, founded in 2018, managing multiple VC funds in the region. We are an experienced team led by industrial veterans who have managed multiple VC funds and invested over dozens of biotech companies. Our StrengthAccess to China market through synergy with TIF: Two organizations, One Team Multi-dimensional value-added post investment to enhance possibility of success and returns Clear investment thesis: In Asia, for Global; Leverage regional synergy and realize future value Best-in-class team in biomed investment with strong track record Our Focus TIBS seeks to invest and build great companies that emerging biotechnology leads to innovative therapeutics to address global unmet medical needs. We focus on incubating and growing potential early-stage biotech start-ups with breakthrough platform technology, differentiated scientific merit and commercial value. Our Core CompetencyValue Discovery: Select investment projects based on precise judgements from in-depth research Project Incubation: Incubate cutting-edge science or outstanding entrepreneurs with innovative approaches. Unique incubation strategy: project management by investment team to increase the asset value; management team recruitment to maximize the equity value and capital efficiency Help entrepreneurs to grow rapidly with proprietary foresight, industry understanding and resources

Curie.Bio is a unique combination of two businesses: we act as both your drug discovery copilot & seed investor. We have some of the world’s best drug hunters, drug makers, experts, and vendors supporting our founders to increase their chances of developing successful medicines. By support, we don’t mean just a couple of hours a month. We are in the trenches with you on a day-to-day basis operating as fully integrated members of your team. We help you choose therapeutic targets, set milestones based on investor feedback, and design experimental plans. We interview and select drug discovery vendors to enable you to hit those milestones. We help identify what expertise needs to be brought in to support your key programs and then get you the right experts. We evaluate incremental data readouts with you to help determine which experiments need to be adjusted from the initial plan. We do real work. When you’re ready for your Series A, we work with you end-to-end on your data room, deck, and pitch. We make investor intros and coach you on how to run an excellent fundraising process to optimize the quality of your round. Curie.Bio’s model gives you a higher chance of success & reduces future dilution. How? By working with us, you make significant progress on your lead program(s) while being extremely capital efficient. We provide real help designing and executing your seed plan, including navigating the bumps, twists, and turns all along the way. This progress leads to better terms when raising a Series A & Series B. Investors now have a clear line of sight to getting your lead program(s) into the clinic. Post Curie.Bio’s seed, founders are positioned to raise significant capital to advance their programs without giving up as much future equity in their company. Simply put: better planning and more progress at the seed means a significantly higher chance of a future where you retain control, upside, and agency over your own company. Why us?Our team has brought over 60 drugs into the clinic with 12 approvals. Our team has founded biotech companies with more than $30 billion in enterprise value. We aim to bring our decades of experience to founders across the globe and have raised over $500m to make our vision a reality. We started with a problem statement: you can’t start a therapeutics company in your garage. Drug discovery is an incredibly complex process with multiple points of failure, particularly in the earliest stages of building a new company. We’re launching with a big idea: if we can help founders avoid mistakes, ensure they have the right data, plan & story, all while retaining the incentive to build their own company, we could in essence, free the founders. We believe the single greatest unlock of innovation in biotech over the next decade will come from creating more founders – more risk takers – more scientists with phenomenal ideas who have the support they need to start their own company.

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field